Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Filgrastim-SBS versus Neupogen in healthy Thai volunteers (fasting, single-dose crossover)
TCTR20211222007Phase 1Not yet recruiting
- Sponsor
- Siam Bioscience Co., Ltd.
- Start
- Jan 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Siam Bioscience Co., Ltd. Primary endpoint: Bioequivalence of Filgrastim-SBS versus Neupogen. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on TCTR20211222007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20211222007.